Cohen JB, Wei L, Maddocks KJ, et al. - Given that both gemcitabine and bendamustine have been assessed in cases with recurrent/refractory Hodgkin lymphoma but not as a doublet, so, researchers investigated the optimal dose and frequency of administration as well as the effectiveness of this combination in patients with recurrent/refractory Hodgkin lymphoma enrolled in this phase 1/2 trial. Up to a maximum dose of gemcitabine (1000 mg/m² on day 1) and bendamustine (120 mg/m² on days 1 and 2) was received by patients, which was ascertained to be the recommended phase 2 dose, delivered every 21 days for up to 6 cycles. There were no dose-limiting toxicities, but grade 3 to 5 pulmonary adverse events occurred in 4 patients. Overall, findings revealed the efficacy of this doublet and it was tolerable as well, but close monitoring for pulmonary toxicity is necessary.